Spatial Concept – Talk Bio

Galapagos Winds Down Cell Therapy Business After Failed Sale, Cuts 365 Jobs and Shutters Global Sites

3 days ago talkbio0Tagged Cell Therapy, Exit, Galapagos, layoffs, restructuring, site closures

Galapagos; cell therapy; exit; layoffs; restructuring; site closures

Unlocking Access: Navigating Pharma’s Regulatory Crossroads – Recent Updates (2025)

1 week ago talkbio0Tagged Access, access strategy, Biosimilars, CRLs, drug importation, drug price, executive actions, Market, Patient access, pharmaceutical regulation, United States Food and Drug Administration

pharmaceutical regulation; market access; drug pricing; FDA transparency; biosimilars; executive actions; market access strategy; drug importation; CRLs; patient access

Somatix Readies Market Launch of First-of-its-Kind Wearable Medication Compliance Feature

2 weeks ago talkbio0Tagged Adherence To Medication Regime, AI-enabled, Detection, digital health, Gestures, partnering with, Presenile dementia, Preventive monitoring, Remote, Roche (company), SafeBeing platform, Somatix, Wearable Electronic Devices

Somatix; wearable technology; medication compliance; AI-enabled; gesture detection; remote patient monitoring; SafeBeing platform; dementia; partnering with Roche; digital health

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

3 weeks ago talkbio0Tagged Cell Therapy, Exit, Industry, layoffs, Massachusetts (geographic location), pipeline shake-up, portfolio reprioritization, R&D, restructuring, strategic, Takeda

Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up

Crystalys Lands $205M to Advance Gout Drug Dotinurad

3 weeks ago talkbio0Tagged Crystalys Therapeutics, dotinurad, expansion, Generalized, Gout Suppressants

Crystalys Therapeutics; Gout Drug; Dotinurad; Global Expansion

AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

1 month ago talkbio0Tagged anifrolumab, AstraZeneca, Clinical Trials, disease activity, Encephalitis, St. Louis, Lupus Erythematosus, Systemic, Phase III, Saphnelo, Self-Injectable, subcutaneous, TULIP-SC trial

AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction

Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless

1 month ago talkbio0Tagged asset, Exit, Lundbeck, Market, neuro-rare diseases, neuro-specialty diseases, NewBridge Pharmaceuticals, offloading, partnerships, restructuring, Swixx Group, Zuellig Pharma

Lundbeck; market exit; asset offloading; partnerships; job cuts; Swixx Group; Zuellig Pharma; NewBridge Pharmaceuticals; restructuring; neuro-rare diseases; neuro-specialty diseases